[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"organ-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:organ-dysfunction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,90,120,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100053926","thoracic-epidural-block-for-severe-acute-pancreatitis-100053926",false,"NCT07697690","Thoracic Epidural Block for Severe Acute Pancreatitis","Thoracic Epidural Block in Patients With Severe Acute Pancreatitis: A Single-Center, Prospective, Randomized, Open-Label, Parallel-Group Trial","TEB-SAP","Inclusion Criteria:\n\n1. Age 18 to 75 years.\n2. Diagnosis of acute pancreatitis, defined by at least two of the following three criteria: typical acute upper abdominal pain; serum amylase and\u002For lipase greater than three times the upper limit of normal; imaging findings consistent with acute pancreatitis on contrast-enhanced CT, MRI, or ultrasound.\n3. Admission or transfer to the study hospital within 72 hours after symptom onset.\n4. Severe acute pancreatitis, or moderately severe acute pancreatitis with early respiratory, cardiovascular, or renal organ dysfunction.\n5. Expected need for hospitalization and continuous clinical observation for at least 72 hours.\n6. Written informed consent provided by the participant or legally authorized representative.\n\nExclusion Criteria:\n\n1. Acute exacerbation of chronic pancreatitis.\n2. Acute pancreatitis associated with pancreatic tumor.\n3. Pregnancy or lactation.\n4. Prior percutaneous abdominal drainage, retroperitoneal drainage, endoscopic drainage, necrosectomy, or surgery before randomization that may substantially affect outcome assessment.\n5. End-stage malignant disease or expected survival less than 3 months.\n6. Severe pre-existing cardiac, pulmonary, hepatic, renal, hematologic, immune, or neurological disease judged by investigators to interfere with outcome assessment.\n7. Severe pre-existing neurological disease that prevents assessment of neurological complications.\n8. Coagulopathy or bleeding risk judged to contraindicate epidural catheterization, including severe thrombocytopenia, elevated INR, prolonged APTT, or other clinically significant coagulation abnormality.\n9. Ongoing anticoagulant or antiplatelet therapy for which discontinuation does not meet neuraxial anesthesia safety requirements.\n10. Puncture site infection, epidural abscess, central nervous system infection, or uncontrolled severe systemic infection.\n11. Severe spinal deformity, prior relevant spinal surgery, or anatomical abnormality that prevents safe thoracic epidural catheterization.\n12. Intracranial hypertension, spinal cord disease, radiculopathy, or other central nervous system disorder that contraindicates neuraxial block.\n13. Known allergy to local anesthetics or other study-related medications.\n14. Refractory shock or severe hemodynamic instability not suitable for thoracic epidural block.\n15. Severe psychiatric disease, cognitive impairment, or inability to cooperate with the study without availability of a legally authorized representative.\n16. Participation in another interventional clinical trial within the previous 3 months.\n17. Any other condition that, in the opinion of the investigators, makes the participant unsuitable for enrollment.","ALL","18 Years","75 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","Severe acute pancreatitis is a serious illness that can cause severe abdominal pain, inflammation, increased abdominal pressure, feeding intolerance, and early problems with breathing, circulation, and kidney function. Patients with severe acute pancreatitis often need treatment in the intensive care unit. Pain control is an important part of treatment, but conventional pain medicines, especially opioids, may cause side effects such as respiratory depression, reduced bowel movement, nausea, vomiting, delirium, and delayed enteral nutrition.\n\nThoracic epidural block is a regional pain-control technique. It may relieve abdominal pain by blocking pain signals and sympathetic nerve activity from the chest and upper abdominal region. This treatment may also reduce the need for systemic opioid medicines, improve bowel function, improve tolerance to enteral nutrition, and reduce the need for early organ support in some patients.\n\nThis study is a single-center, prospective, randomized, open-label, parallel-group trial. Adult patients with severe acute pancreatitis will be randomly assigned to either a thoracic epidural block group or a conventional analgesia group. Patients in the thoracic epidural block group will receive continuous thoracic epidural infusion of ropivacaine alone, without epidural opioids such as sufentanil, fentanyl, or morphine. Intravenous pain medicines will be used only before epidural block initiation, as rescue analgesia when epidural pain control is inadequate, or after epidural block is paused, fails, or is discontinued. Patients in the conventional analgesia group will receive standard pain treatment according to clinical practice.\n\nThe main goal of this study is to determine whether thoracic epidural block can increase the number of days patients are alive and free from ICU-level organ support during the first 14 days after randomization. ICU-level organ support includes invasive mechanical ventilation, noninvasive ventilation, vasoactive or inotropic drug infusion, and renal replacement therapy. The study will also evaluate pain scores, opioid consumption, enteral nutrition tolerance, intra-abdominal pressure, organ function scores, complications, length of ICU and hospital stay, hospital cost, 28-day mortality, and adverse events related to thoracic epidural block.",[28,29,30],"Severe Acute Pancreatitis","Organ Dysfunction","Organ Support",[32,33,34,35,36],"Severe acute pancreatitis","Thoracic epidural block","Ropivacaine","Organ support-free days","Opioid consumption","NOT_YET_RECRUITING","2026-07-07",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":22},"2026-08-01",{"date":45,"type":22},"2028-09-01",{"name":47,"class":48},"First People's Hospital of Chenzhou","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100602123","icu-background-early-awareness-for-critical-deterioration-100602123","NCT07119411","ICU Background Early Awareness for Critical deterioratiON","ICU Background Early Awareness for Critical deterioratiON (BEACON)","BEACON","Inclusion Criteria:\n\n* admission to intensive care unit\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* presence of documented refused general consent form (at database closure)\n* admission for the sole purpose of dying\u002Forgan donation or evaluation of such",true,{"count":59,"type":22},1962,"OBSERVATIONAL","The study will compare ICU sub-units, those with additional support of a clinician awareness system, ICU Beacon, and those receiving the standard of care. The win-ratio composite outcome will be assessed by comparing patients by study group and stratified by APACHE score at admission.",[63,64,65,29,66],"Respiratory Failure","Circulatory Failure","Mortality","Organ Failure, Multiple",[68,69,70,71,72,73,74,75,76,77,78],"icu","respiratory failure","circulatory failure","early warning system","prevention","prediction","risk prediction","organ failure","multi-organ failure","win-ratio","ICU Beacon","RECRUITING","2026-06-12",{"date":82,"type":41},"2026-06-15",{"date":84,"type":41},"2025-12-01",{"date":86,"type":22},"2027-11-01",{"name":88,"class":48},"ETH Zurich",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":116,"leadSponsor":118,"locationsCount":89},"100616030","validation-of-sofa-2-for-mortality-and-sepsis-3-prevalence-in-turkey-100616030","NCT07300306","Validation of SOFA-2 for Mortality and Sepsis-3 Prevalence in Turkey","Validation of the SOFA-2 Score for 30-Day Mortality in Intensive Care Units in Turkey and Determination of Sepsis-3 Prevalence - A Multicenter Hybrid Observational Study.","TURK-SOFA2","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Admitted to the Intensive Care Unit (ICU) during the specified study recruitment window.\n* For the Validation Cohort: Patients staying in the ICU for at least 24 hours.\n* For the Point Prevalence Cohort: Patients present in the ICU at 08:00 AM on the designated \"Index Day\" or admitted within the subsequent 24 hours.\n\nExclusion Criteria:\n\n* Patients younger than 18 years of age.\n* Patients admitted to Pediatric Intensive Care Units.\n* Patients admitted to Coronary Care Units (CCU).\n* Patients admitted to Cardiovascular Surgery Intensive Care Units.\n* Patients admitted solely for the purpose of organ donation.\n* Patients with missing core data components required for score calculation.",{"count":99,"type":22},2500,"The goal of this observational study is to validate the effectiveness of the new SOFA-2 score in predicting mortality and to determine the current frequency of sepsis in adult patients admitted to Intensive Care Units (ICUs) in Turkey. The main questions it aims to answer are:\n\n* Does the SOFA-2 score accurately predict 30-day mortality in ICU patients?\n* What is the prevalence of Sepsis-3 and septic shock in Turkish ICUs?\n\nResearchers will compare the new SOFA-2 score to the existing SOFA-1 score to see if the new score provides better predictive accuracy for patient outcomes.\n\nParticipants will not receive any experimental intervention. Researchers will collect data from routine medical care, including:\n\n* Vital signs, laboratory test results, and details of organ support (such as mechanical ventilation or dialysis) during the first 24 hours of admission.\n* Survival status at 30 days.",[102,103,104,29],"Sepsis","Septic Shock","Critical Illness",[106,107,108,109,110,111],"SOFA-2 Score","Sepsis-3","Intensive Care Unit","Mortality Prediction","Organ Failure Assessment","Validation Study","2026-05-04",{"date":114,"type":41},"2026-05-08",{"date":112,"type":41},{"date":117,"type":22},"2026-07",{"name":119,"class":48},"Marmara University",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":128,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100598171","organ-dysfunction-score-for-obstetric-patients-100598171","NCT07068022","Organ Dysfunction Score for Obstetric Patients","Development and Validation of an Obstetric Organ Dysfunction Score to Predict Mortality in Intensive Care Unit: A Multicenter, Prospective, Cohort Study","SOFA-OBS","Inclusion Criteria:\n\nAll of the following=\n\n* Pregnant (at any gestational age) or post-partum patients (at ≤3 days postpartum)\n* ≥ 18 years old\n* Requiring admission to ICU for any reason\n* Staying in the ICU for ≥ 24h\n* Giving her consent to participate. Patients will be recruited consecutively until reaching the sample size.\n\nExclusion Criteria:\n\nAny of the following=\n\n* Patients \\\u003C18 years old\n* Non-pregnant patients\n* ≥ 4 days postpartum\n* Patients or surrogates not giving consent to participate\n* ICU-LOS \\\u003C 24 h","FEMALE",{"count":130,"type":22},130,"The goal of this observational study is to develop and evaluate an organ dysfunction score adapted to pregnancy and early puerperium (SOFA-OBS) that also incorporates a non-invasive tool to evaluate respiratory function (pulse oximeter).\n\nThe main question it aims to answer is: Does an organ dysfunction score adapted to pregnant and postpartum patients have a higher capacity to predict mortality than a non-adjusted organ dysfunction score? Participants: Patients requiring ICU (Intensive Care Units) admission, who are either pregnant or postpartum (up to 3 days after giving birth). The investigators aimed to include 130 participants.\n\nThe investigators will only collect participants' data and laboratory results that ICU doctor usually need for clinical practice. No additional interventions are required. Moreover, the investigators will evaluate if measuring participants' oxygenation through a non-invasive tool (pulse oximeter) is equally effective as measuring oxygenation by an arterial puncture.\n\nBackground: When managing severely ill patients in ICU, the investigators often use what it is called scores. Scores refer to a numerical value assigned to a patient's condition, which often predict outcome. The Sequential Organ Failure Assessment (SOFA) score is a scoring system that assess severity of organ dysfunction (in liver, kidney, blood pressure, respiratory, neurologic and platelets). It also identifies patients with severe infections (sepsis) and patients with bad outcomes.\n\nPatients undergoing pregnancy or early postpartum develop physiological changes, such us a decrease in creatinine (a laboratory test measuring kidney function) and a decrease in blood pressure during the second trimester. These changes are not considered by the SOFA score. Actually, there is not an organ dysfunction score adapted to pregnant\u002Fpostpartum patients to be used in the ICU. Moreover, a blood sample taken by arterial puncture is required to evaluate respiratory function by the SOFA score, which is a painful procedure. Instead, the investigators could evaluate respiratory function using a pulse oximeter, which measures peripheral oxygen saturation without needing an arterial puncture.\n\nPotential benefits: A SOFA-OBS would hopefully become a more precise tool than general SOFA to evaluate organ dysfunction and to predict outcome among these patients. It would also help to detect sepsis earlier and treat it promptly, which might help reducing its mortality.",[133,134,29,135,102],"Pregnancy","Postpartum","Critical Care, Intensive Care",[137,133,134,138,108,139,140,141,142,65,102,143,144],"Sequential Organ Failure Assessment score","Critical care","Creatinine","Peripheral oxygen saturation","Hypotension","Maternal mortality","Septic shock","Multicenter study","2026-04-22",{"date":147,"type":41},"2026-04-28",{"date":149,"type":41},"2025-10-06",{"date":151,"type":22},"2027-02-28",{"name":153,"class":48},"Daniela Vasquez",18,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":180,"leadSponsor":182,"locationsCount":184},"100599512","the-effect-of-the-timing-of-supplemental-parenteral-nutrition-on-the-prognosis-of-critically-ill-patients-t-spn-100599512","NCT07085455","The Effect of the Timing of Supplemental Parenteral Nutrition on the Prognosis of Critically Ill Patients (T-SPN)","The Effect of the Timing of Supplemental Parenteral Nutrition on the Prognosis of Critically Ill Patients (T-SPN): A Multicenter Randomized Controlled Trial","Inclusion Criteria：\n\n1. Age ≥ 18 years\n2. Failure of one or more organ systems within 24 hours of ICU admission, defined as Sequential Organ Failure Assessment (SOFA) score ≥ 2 in any single organ system\n3. Expected ICU stay \\> 72 hours\n4. Able to initiate early enteral nutrition (EN) within 48 hours of ICU admission\n5. Enteral nutrition providing \\\u003C50% of target caloric requirements within 72 hour Exclusion Criteria\n\n1.Full oral intake or tolerance of full-dose EN; no need for SPN 2.Receiving palliative care or expected to die within 72 hours 3.Pregnant or lactating women 4.Long-term use of systemic corticosteroids or other immunosuppressive agents 5.Known malignancy currently receiving radiotherapy or chemotherapy 6.Contraindications to parenteral nutrition (PN) 7.Participation in another interventional clinical trial",{"count":163,"type":22},946,[25],"This multicenter, randomized controlled trial aims to evaluate whether early initiation of supplemental parenteral nutrition (SPN) (on day 4 of ICU admission) compared to late initiation (on day 8) can reduce 28-day all-cause mortality in critically ill patients. Secondary objectives include assessing the effects of early SPN on long-term functional outcomes (2-year EQ-5D-5L scores), mortality at various timepoints (ICU, 28-day, 90-day, 180-day, and 2-year), ICU length of stay, serum prealbumin levels (days 8 and 28), skeletal muscle measurements (diaphragm thickness, biceps, quadriceps, and rectus femoris cross-sectional area), incidence of ICU-acquired infections, adverse events (e.g., hyperglycemia, hypoglycemia, dyslipidemia, liver dysfunction), and ventilator-free days within 28 days.\n\nEligible patients are adults (≥18 years) with at least one organ failure (SOFA score ≥2) within 24 hours of ICU admission, expected to remain in the ICU for \\>72 hours, and unable to reach 50% of caloric target via enteral nutrition (EN) within the first 72 hours. A total of 946 patients will be enrolled and randomized to receive either early SPN (day 4) or late SPN (day 8) in addition to standard EN. Follow-up will include in-hospital assessments and telephone follow-ups at 28, 90, 180 days, and 2 years. The study hypothesizes that early SPN may improve short-term survival and nutritional\u002Fmuscle status, though its impact on long-term quality of life remains to be determined.",[104,29,167,168],"Enteral Nutrition Intolerance","Inadequate Nutritional Intake",[170,171,172,173,174,175],"Nutritional support","Supplementary parenteral nutrition","Early enteral nutrition","Severe patients","critical care","intensive care","2025-09-09",{"date":178,"type":41},"2025-09-15",{"date":176,"type":41},{"date":181,"type":22},"2029-07-20",{"name":183,"class":48},"Dong Zhang",2]